Lipid oxidation products and atherosclerosis

Vascular Pharmacology

Volumn 38, Issue 4, 2002, Pages 187-191

  Berliner, Judith ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; LIPID;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL INTAKE; DISEASE ASSOCIATION; EDITORIAL; FOAM CELL; HUMAN; HYPERCHOLESTEROLEMIA; LIPID OXIDATION; LIPID STORAGE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOSIS; VASCULAR LESION; ANIMAL; ARTERIOSCLEROSIS; DISEASE COURSE; LIPID METABOLISM; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; DISEASE PROGRESSION; HUMANS; LIPID METABOLISM; OXIDATION-REDUCTION;

EID: 0036549988     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1537-1891(02)00168-4     Document Type: Editorial

References (31)

1. Ahmed Z., Ravandi A., Maguire G.F., Emili A., Draganov D., LaDu B.N., Kuksis A., Connelly P.W. Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J. Biol. Chem. 276:2001;24473-24481.
2. Antonov A.S., Munn D.H., Kolodgie F.D., Virmani R., Gerrity R.G. Aortic endothelial cells regulate proliferation of human monocytes in vitro via a mechanism synergistic with macrophage colony-stimulating factor. Convergence at the cyclin E/p27(Kip1) regulatory checkpoint. J. Clin. Invest. 99:1997;2867-2876.
3. Berliner J.A., Subbanagounder G., Leitinger N., Watson A.D., Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc. Med. 11:2001;142-147.
4. Bey E.A., Cathcart M.K. In vitro knockout of human p47phox blocks superoxide anion production and LDL oxidation by activated human monocytes. J. Lipid Res. 41:2000;489-495.
5. Bjorkhem I., Diczfalusy U., Lutjohann D. Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Curr. Opin. Lipidol. 10:1999;161-165.
6. Brown A.J., Leong S.L., Dean R.T., Jessup W. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. J. Lipid Res. 38:1997;1730-1745.
7. Fang X., Kaduce T.L., VanRollins M., Weintraub N.L., Spector A.A. Conversion of epoxyeicosatrienoic acids (EETs) to chain-shortened epoxy fatty acids by human skin fibroblasts. J. Lipid Res. 41:2000;66-74.
8. Febbraio M., Podrez E.A., Smith J.D., Hajjar D.P., Hazen S.L., Hoff H.F., Sharma K., Silverstein R.L. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J. Clin. Invest. 105:2000;1049-1056.
9. Friedman P., Horkko S., Steinberg D., Witztum J.L., Dennis E.A. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids: importance of Schiff base formation and Aldol condensation. J. Biol. Chem. 14:2001;14.
10. Galis Z.S., Sukhova G.K., Lark M.W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94:1994;2493-2503.
11. Garcia-Cruset S., Carpenter K.L., Guardiola F., Mitchinson M.J. Oxysterols in cap and core of human advanced atherosclerotic lesions. Free Radic. Res. 30:1999;341-350.
12. Gaut J.P., Heinecke J.W. Mechanisms for oxidizing low-density lipoprotein. Insights from patterns of oxidation products in the artery wall and from mouse models of atherosclerosis. Trends Cardiovasc. Med. 11:2001;103-112.
13. Goyal J., Wang K., Liu M., Subbaiah P.V. Novel function of lecithin-cholesterol acyltransferase. Hydrolysis of oxidized polar phospholipids generated during lipoprotein oxidation. J. Biol. Chem. 272:1997;16231-16239.
14. Huber J., Vales A., Mitulovic G., Blumer M., Schmid R., Witztum J.L., Binder B.R., Leitinger N. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler. Thromb. Vasc. Biol. 22:2002;101-107.
15. Hulten L.M., Lindmark H., Diczfalusy U., Bjorkhem I., Ottosson M., Liu Y., Bondjers G., Wiklund O. Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. J. Clin. Invest. 97:1996;461-468.
16. Jessup W., Kritharides L. Metabolism of oxidized LDL by macrophages. Curr. Opin. Lipidol. 11:2000;473-481.
17. Kojda G., Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc. Res. 43:1999;562-571.
18. Mackness M.I., Mackness B., Durrington P.N., Fogelman A.M., Berliner J., Lusis A.J., Navab M., Shih D., Fonarow G.C. Paraoxonase and coronary heart disease. Curr. Opin. Lipidol. 9:1998;319-324.
19. Mashima R., Witting P.K., Stocker R. Oxidants and antioxidants in atherosclerosis. Curr. Opin. Lipidol. 12:2001;411-418.
20. Napoli C., Witztum J.L., Calara F., de Nigris F., Palinski W. Maternal hypercholesterolemia enhances atherogenesis in normocholesterolemic rabbits, which is inhibited by antioxidant or lipid-lowering intervention during pregnancy: an experimental model of atherogenic mechanisms in human fetuses. Circ. Res. 87:2000;946-952.
21. Navab M., Hama S.Y., Cooke C.J., Anantharamaiah G.M., Chaddha M., Jin L., Subbanagounder G., Faull K.F., Reddy S.T., Miller N.E., Fogelman A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J. Lipid Res. 41:2000;1481-1494.
22. Pratico D., Iuliano L., Mauriello A., Spagnoli L., Lawson J.A., Rokach J., Maclouf J., Violi F., FitzGerald G.A. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100:1997;2028-2034.
23. Reape T.J., Groot P.H. Chemokines and atherosclerosis. Atherosclerosis. 147:1999;213-225.
24. Schultz D., Harrison D.G. Quest for fire: seeking the source of pathogenic oxygen radicals in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20:2000;1412-1413.
25. Shih D.M., Xia Y.R., Wang X.P., Miller E., Castellani L.W., Subbanagounder G., Cheroutre H., Faull K.F., Berliner J.A., Witztum J.L., Lusis A.J. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275:2000;17527-17535.
26. Srivastava S., Conklin D.J., Liu S.Q., Prakash N., Boor P.J., Srivastava S.K., Bhatnagar A. Identification of biochemical pathways for the metabolism of oxidized low-density lipoprotein derived aldehyde-4-hydroxy trans-2-nonenal in vascular smooth muscle cells. Atherosclerosis. 158:2001;339-350.
27. Stafforini D.M., McIntyre T.M., Zimmerman G.A., Prescott S.M. Platelet-activating factor acetylhydrolases. J. Biol. Chem. 272:1997;17895-17898.
28. Subbanagounder G., Wong J.W., Lee H., Faull K.F., Miller E., Witztum J.L., Berliner J.A. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis: formation of these oxidized phospholipids in response to interleukin-1{beta}. J. Biol. Chem. 19:2001;19.
29. Suzuki H., Kurihara Y., Takeya M., Kamada N., Kataoka M., Jishage K., Ueda O., Sakaguchi H., Higashi T., Suzuki T., Takashima Y., Kawabe Y., Cynshi O., Wada Y., Honda M., Kurihara H., Aburatani H., Doi T., Matsumoto A., Azuma S., Noda T., Toyoda Y., Itakura H., Yazaki Y., Kodama T.et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386:1997;292-296.
30. Witztum J.L., Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc. Med. 11:2001;93-102.
31. Yamada Y., Yoshida H., Ichihara S., Imaizumi T., Satoh K., Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis. 150:2000;209-216.